A SiftingSignal publication/ Edited by Simon Mathews, MD

The week in GI, filtered to what is worth knowing.

Every week, 100+ papers from 25+ top GI and medical journals, transparently scored and physician-vetted. The signal, not the noise.

This week, in numbers

Issue №20 · week of Nov 15, 2026See the trends →
Top journals this week: Lancet / Nature Medicine / J Hepatology / Lancet GH
Selectivity
11.7%
19 in the issue of 162 screened
in the issue 19in depth 36held 1filtered out 106
88.3% of what published this week did not make the issue. That filter is the product. A further 36 cleared the bar and are carried in one line each, in full on the subspecialty pages.
How this week moves the standard
Changes practice 0
No paper this week forces an outright change to the standard. That is the usual, honest result.
Each paper is matched to the guideline that governs its question, then placed by how it moves it. 11 of the 19 cards in the issue are matched to a standard, and each of those quotes it with its source and review date. From issue 14, every match is independently re-checked, so this bar reads lower than in earlier issues. Click a segment to filter the issue.
The signal map
647891narrative reviewRCT →Clinical utilityEvidence strength
Each dot is a paper: evidence strength across, clinical utility up (what you can do with it, what rides on it, how many patients, how new), area = the journal's impact factor, colour = subspecialty. A dark ring marks a paper that refines or changes its standard of care. The vertical scale spans this week's cards and its numbers are the real scores out of 100. Click a dot to open its card.

What to know this week

the top-scored · the 5-minute version

in UC, adenomas (HR 9.8) and low-grade dysplasia were the strongest colorectal cancer predictors, colonoscopy after positive mt-sDNA test is warranted even with prior normal colonoscopy, and DOACs vs warfarin in cirrhosis: associated with less bleeding in AF, but higher mortality and fewer transplants in venous thrombosis.

The 19 in the issue this week, ranked by signal score. Each anchored to the relevant standard of care. All in full below; 36 more, read and scored the same way, in one line each at the foot of the issue.

Your subspecialty, the takeaways
IBD14Hepatology14Esophagus/Reflux4Pancreas/Biliary5Endoscopy10Motility1Colorectal5Nutrition2
Type

This week to know

the 6 strongest this week · each scored 0 to 100 on what it lets you do, who it touches, the stakes, and how well the evidence backs it
IBD prospective cohort · n=1,286 · Nov 9, 2026 · Endoscopy · IF 11.8

Mucosal abnormalities as key predictive factors of colorectal cancer in ulcerative colitis.

New evidenceulcerative colitiscolorectal cancerdysplasia surveillanceepidemiology
Clinical takeawayTreat prior low-grade dysplasia and adenomas as the strongest CRC risk markers in UC; the authors conclude their findings do not support prevailing recommendations for endoscopic surveillance, though the study did not test surveillance intervals.
What it foundLow-grade dysplasia predicted a 3-fold and adenomas a 10-fold excess rate of CRC in UC (HR 9.8, 95%CI 5.2-18.6), while severe macroscopic or microscopic inflammation showed no significant association.
ContextScandinavian population-based case-cohort (566 CRC cases, 720 sub-cohort members, median follow-up 15.0 years); pancolitis carried higher risk than proctitis (HR 2.3), and biologics or immunomodulators did not significantly reduce the CRC rate.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Högdén A … Blom J · Endoscopy · IF 11.8 · PubMed ↗Permalink
Colorectal retrospective · n=1,733 · Nov 13, 2026 · Clin Transl Gastro · IF 3.4

Colonoscopy outcomes after positive multi-target stool DNA testing in patients with and without a prior normal colonoscopy: Data from the New Hampshire Colonoscopy Registry.

New evidencecolorectal cancer screeningbiomarkerepidemiology
What it foundPatients with a prior normal colonoscopy had 19.1% prevalence of advanced colorectal neoplasia after a positive mt-sDNA test, half the odds of advanced findings compared to those without prior colonoscopy (OR 0.51; 95% CI 0.41-0.62).
ContextThis literature reports that the yield of advanced neoplasia following a positive multi-target stool DNA test in patients with a prior normal colonoscopy remains an area of investigation.
Measured against the standard of care· USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin)

… Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. … ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

U.S. Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. Screening at 45-49 is a weaker recommendation than at 50-75. Colonoscopy every 10 years and annual FIT are the Tier 1 cornerstones. Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. Capsule colonoscopy every 5 years is Tier 3. Any abnormal non-colonoscopy test requires a diagnostic colonoscopy, and a stool test should not be offered to a patient who would decline follow-up colonoscopy. Patients who are up to date with negative prior screening, particularly a high-quality colonoscopy, may consider stopping at 75 or when life expectancy is under 10 years. Decisions at 76-85 are individualized by health and prior screening, and screening after 85 is not recommended. The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. It adds the next-generation mt-sDNA test and the multitarget stool RNA test (ColoSense), both every 3 years, and it adds an FDA-approved blood-based cfDNA test (Shield) only for people who decline or do not complete visual or stool screening. ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin) · reviewed 2026-10-11 ↗
Anderson JC … Butterly LF · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
Hepatology prospective cohort · n=93,663 · Nov 11, 2026 · Clin Gastro Hep · IF 16.2

Oral Anticoagulant Choice Across Indications in Cirrhosis: A US Nationwide Cohort Study.

New evidencecirrhosisportal hypertensionliver transplantepidemiology
Clinical takeawayThese propensity-matched associations support indication-specific anticoagulant choice in cirrhosis: in AF, DOACs were associated with less bleeding at similar mortality; in DVT/PE or PVT, DOAC initiators had higher mortality and lower transplant access than warfarin initiators.
What it foundAmong 93,663 initiators, DOACs vs warfarin in AF were associated with similar mortality and transplant rates and lower major and non-gastrointestinal bleeding, including intracranial hemorrhage. In DVT/PE and PVT, DOACs were associated with higher mortality (sHR 1.21 [95% CI 1.10-1.34] and 1.43 [1.24-1.65]) and lower transplant rates (sHR 0.25 [0.17-0.38] and 0.23 [0.17-0.32]); gastrointestinal bleeding was higher with DOACs in PVT (sHR 1.26 [1.06-1.50]).
ContextPartly an allocation effect: in a waitlisted cohort (n=284), warfarin-related INR elevation, which inflates MELD, mediated 29% of the transplant-access difference; the authors call for reconsidering INR handling in US transplant allocation.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Tanaka T … Axelrod D · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatology rct · n=84 · Nov 12, 2026 · Am J Gastro · IF 9.8

Efficacy and safety of dabigatran in cirrhosis with chronic portal vein thrombosis: A randomized, placebo-controlled double-blind trial (DAB-PVT).

New evidencecirrhosisportal hypertensionvariceal bleeding
Clinical takeawayDabigatran 150 mg twice daily can be considered for recanalizing chronic PVT in Child-Pugh A/B cirrhosis on the strength of this placebo-controlled trial (42 patients per arm); the fewer bleeding events and better CTP and ALBI scores are exploratory.
What it foundComplete recanalization at 12 months: 27/42 (64.3%) with dabigatran 150 mg twice daily vs 9/42 (21.4%) with placebo (p<0.001). Variceal bleeding episodes were fewer (3 vs 12; p=0.008), a clinical-event difference the authors call exploratory.
ContextDOACs are emerging options for PVT in cirrhosis, with uncertain safety and efficacy. Patients had a median CTP score of 8 and 45.2% had prior variceal bleeding; MELD trajectories did not differ between groups.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Meena BL … Sarin SK · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Colorectal prospective cohort · n=17,068 · Nov 11, 2026 · Am J Clin Nutrition · IF 6.5

Folate and folic acid intake in relation to molecular subtypes of colorectal cancer: pooled analyses of up to 8970 cases and 8098 control participants.

New evidenceepidemiologybiomarkermicrosatellite instabilitycolorectal cancer
Clinical takeawayNo clinical action yet: pooled observational data from case-control and cohort studies, with intake from food frequency questionnaires or diet histories; the study does not test giving folate or folic acid.
What it foundTotal folate intake and folate supplement use were inversely associated with colorectal cancer risk, with a stronger inverse association for CIMP-low/negative vs. CIMP-high tumors (pdifference=0.07). Dietary folate showed a weaker association, and there was a null association for the Jass Type 2 subtype.
ContextHigher folate intake has been associated with modest reductions in colorectal cancer risk; across 8970 cases and 8098 controls, the authors judge the putative protective effect broad, not limited to BRAF, KRAS, MSI or CIMP subtypes.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Van Guelpen B … Peters U · American Journal of Clinical Nutrition · IF 6.5 · PubMed ↗Permalink
Endoscopy rct · n=551 · Nov 12, 2026 · GIE · IF 8.0

Effect of Dose Interval on Split-dose Bowel Preparation: A Multicenter Noninferiority Randomized Controlled Trial.

New evidencecolonoscopyendoscopy qualitycolorectal cancer screening
Clinical takeawayConsider offering patients flexibility in OSS split-dose timing (6-8 hours or 10-12 hours) based on convenience, as both intervals achieve similar bowel preparation quality and safety.
What it foundShort-interval (6-8 hours) and long-interval (10-12 hours) OSS split-dose regimens had comparable adequate bowel preparation rates (96.0% vs. 96.7%, difference -0.7%, 95% CI -3.8% to 2.4%).
ContextConfirms that shorter intervals for split-dose OSS are non-inferior to longer intervals, refining current practice by supporting flexible timing without compromising efficacy.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Sui X … Bai Y · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink

The read

the next 13, in full

IBD· 2

IBD retrospective · n=4,019 · Nov 12, 2026 · Am J Gastro · IF 9.8

Comparative Risk of Cancer with non-TNF Advanced Therapies Versus Anti-TNF Therapy in Inflammatory Bowel Disease.

New evidencebiologicsanti-TNFvedolizumabJAK inhibitors
Clinical takeawayFor IBD patients with cancer concerns, these retrospective data are reassuring for anti-IL therapy: no evidence of increased cancer risk versus anti-TNF, and lower non-skin cancer (HR 0.28, 95% CI 0.09-0.81).
What it foundAnti-IL therapy had a lower hazard of non-skin cancer compared to anti-TNF therapy (HR 0.28; 95% CI 0.09-0.81), with no significant difference in skin cancer risk (HR 1.56; 95% CI 0.39-6.15). There was a trend towards a lower hazard of all cancers among anti-IL users compared to anti-TNF users (HR 0.47; 95% CI 0.21-1.04), which was significant on sensitivity analyses.
ContextDirect comparisons of incident cancer between anti-IL agents or vedolizumab and anti-TNFs were lacking; the cohort covered 4,019 therapy starts with mean duration 1096 days.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

… Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). … Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Ibrahim MK … Ananthakrishnan AN · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
IBD retrospective · n=44 · Nov 13, 2026 · Inflamm Bowel Dis · IF 4.5

Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study.

New evidenceulcerative colitisbiologicsvedolizumabustekinumab
Clinical takeawayA cyclosporine-to-biologic bridge had acceptable safety in this single-centre series of 44 responders, with 46% treatment persistence at 12 months; the vedolizumab-ustekinumab difference is exploratory, and adverse events were mainly renal or neurological.
What it foundCyclosporine-to-biologic bridging in biologic-exposed ASUC yielded 73% colectomy-free survival at 12 months (95% CI, 61-88). Exploratory analyses suggested higher colectomy-free survival with vedolizumab than ustekinumab (79% vs 47%, log-rank P = .03), though comparisons remain exploratory. Adverse events were predominantly renal or neurological.
ContextThis study provides evidence supporting cyclosporine-to-biologic bridging in biologic-exposed ASUC, refining prior limited data on maintenance strategies post-cyclosporine response, though comparisons between maintenance therapies remain exploratory.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Nuzzo A … Bazin T · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink

Hepatology· 5

Hepatology retrospective · n=2,221 · Nov 13, 2026 · J Clin Gastro · IF 2.9

Impact of Guideline-Based Acute Kidney Injury Care Processes on Outcomes in Hospitalized Patients With Decompensated Cirrhosis.

New evidencecirrhosishealth servicesepidemiology
Clinical takeawayThe authors suggest targeting diuretic avoidance and timely postdischarge visits, both expert-recommended process measures; follow-up within 15 days was uncommon (primary care 28%, gastroenterology/hepatology 6%), and the evidence is retrospective.
What it foundAmong 2221 patients with ascites and AKI at Veterans Administration hospitals, diuretic avoidance was associated with AKI resolution (OR 1.14, 95% CI 1.02-1.28), and timely postdischarge visits with primary care (HR 0.53, 95% CI 0.43-0.67) or gastroenterology/hepatology (HR 0.44, 95% CI 0.29-0.66) with lower 90-day mortality.
ContextConfirms expert recommendations for AKI management in cirrhosis, providing evidence linking specific process measures to improved outcomes in hospitalized cirrhosis patients with AKI.
Emergingsuggested applicable standard· International Club of Ascites (ICA) & Acute Disease Quality Initiative (ADQI), "Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting," Journal of Hepatology, 2024

Per the 2024 ADQI-ICA joint consensus (which updates the 2015 ICA-AKI criteria referenced in AASLD 2021), in a patient with cirrhosis and ascites: DIAGNOSE HRS-AKI when all of (a) cirrhosis with ascites; (b) AKI by KDIGO/ICA criteria, serum creatinine rise ≥0.3 mg/dL (26.5 µmol/L) within 48h or ≥50% from a baseline known or presumed within the prior 7 days, and/or urine output ≤0.5 mL/kg/h for ≥6h (strong recommendation, grade A); (c) absence of improvement in serum creatinine and/or urine output within 24h following adequate volume resuscitation WHEN CLINICALLY INDICATED, the consensus recommends AGAINST systematic 48h albumin administration as a diagnostic requisite (strong recommendation, grade D), and only where volume status is equivocal is a single fluid challenge (250-500 mL crystalloid, or 1-1.5 g/kg of 20-25% albumin) assessed within 24h; and (d) absence of strong evidence for an alternative primary cause of AKI (e.g., septic shock requiring vasopressors, acute glomerular injury, obstruction, or nephrotoxin-induced AKI) (not graded). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Per the 2024 ADQI-ICA joint consensus (which updates the 2015 ICA-AKI criteria referenced in AASLD 2021), in a patient with cirrhosis and ascites: DIAGNOSE HRS-AKI when all of (a) cirrhosis with ascites; (b) AKI by KDIGO/ICA criteria, serum creatinine rise ≥0.3 mg/dL (26.5 µmol/L) within 48h or ≥50% from a baseline known or presumed within the prior 7 days, and/or urine output ≤0.5 mL/kg/h for ≥6h (strong recommendation, grade A); (c) absence of improvement in serum creatinine and/or urine output within 24h following adequate volume resuscitation WHEN CLINICALLY INDICATED, the consensus recommends AGAINST systematic 48h albumin administration as a diagnostic requisite (strong recommendation, grade D), and only where volume status is equivocal is a single fluid challenge (250-500 mL crystalloid, or 1-1.5 g/kg of 20-25% albumin) assessed within 24h; and (d) absence of strong evidence for an alternative primary cause of AKI (e.g., septic shock requiring vasopressors, acute glomerular injury, obstruction, or nephrotoxin-induced AKI) (not graded). HRS-AKI is a phenotype specific to advanced cirrhosis and ascites: coexisting CKD, tubular injury or proteinuria do NOT exclude it, and it may coexist with, or be superimposed on, other AKI etiologies rather than requiring pure exclusion. TREAT: immediately on diagnosis start a vasoconstrictor plus 20-25% albumin (strong recommendation, grade A). Terlipressin is first-line, continuous IV infusion 2-12 mg/day, titrated up by ≥2 mg/day every 24h to a maximum 12 mg/day if serum creatinine has not fallen ≥25%; or IV bolus 1-2 mg every 6h, escalated from 1 mg to 2 mg every 6h on that same ≥25% serum-creatinine response threshold, with the 12 mg/day maximum applying only to continuous infusion and not to bolus dosing. If terlipressin is unavailable or contraindicated, norepinephrine (continuous infusion 0.5-3 mg/h, up-titrated 0.5 mg/h every 4h to raise MAP ≥10 mmHg; requires ICU care and a central line) may be more appropriate. Midodrine 7.5-15 mg PO every 8h plus octreotide 100-200 µg SC every 8h with albumin is third-line, considered only if terlipressin is contraindicated AND transfer to ICU for norepinephrine is not possible. Give 20-25% albumin 20-40 g/day with any vasoconstrictor, adjusted daily to volume status and withheld for fluid overload/pulmonary edema. Discontinue vasoconstrictors when serum creatinine returns to within 0.3 mg/dL of baseline, for a severe adverse reaction, if kidney function does not improve after 48h at maximum tolerated dose, if RRT is indicated, or at a maximum of 14 days of therapy (strong recommendation, grade B). Initiation of RRT should be individualized to clinical context and anticipated or observed life-threatening AKI-related complications (best-practice statement) rather than framed strictly as a transplant-bridge measure. Recommend expedited evaluation for liver transplantation following an episode of AKI (best-practice statement); LT in selected patients is the definitive treatment for HRS-AKI regardless of vasoconstrictor response (strong recommendation, grade A), with vasoconstrictors serving as a bridge to transplantation or renal recovery rather than a cure.

International Club of Ascites (ICA) & Acute Disease Quality Initiative (ADQI), "Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting," Journal of Hepatology, 2024 · reviewed 2026-07-23 ↗
Patidar KR … Hernaez R · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Hepatology review · Nov 13, 2026 · J Gastro Hep · IF 3.5

Metabolic Dysfunction as a Rising Barrier to HBV Elimination.

New evidenceviral hepatitishepatocellular carcinomaMASLD
Clinical takeawayThe authors propose assessing and correcting metabolic dysfunction as part of CHB care, and including CHB patients in metabolic-therapy trials, so success is defined by liver outcomes, not the virus alone.
What it foundMetabolic dysfunction lowers adult vaccination response compared to non-metabolic dysfunction, enters three of the four WHO treatment eligibility routes (specifics in source), and increases HCC risk during antiviral therapy in CHB patients.
ContextChallenges current CHB care by highlighting the overlooked impact of metabolic dysfunction on treatment eligibility, HCC risk, and outcomes in CHB patients.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026

… Rec 9: in HBV-HCV coinfection, AASLD recommends treating HCV and suggests HCC surveillance per HBV mono-infection criteria. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

The 2026 AASLD/IDSA guideline addresses six PICO questions only; it states explicitly that all other 2018 AASLD recommendations for CHB management remain applicable, and that screening/diagnosis were out of scope. Baseline evaluation and the standard treatment indications (cirrhosis with detectable HBV DNA; HBeAg-positive immune-active with ALT >2x ULN and HBV DNA >20,000 IU/mL; HBeAg-negative immune-active with ALT >2x ULN and HBV DNA >2,000 IU/mL; prophylaxis for reactivation risk during immunosuppression) derive from the 2018 document, not this update, which lists 'treatment of HBeAg-positive and -negative immune active CHB with ALT >2x ULN', treatment of children, treatment of cirrhosis, low-level viremia, virologic breakthrough, and special populations (transplant, acute HBV, HCV/HDV/HIV coinfection) as topics 'well covered in previous AASLD 2018 Guidance and for which recommendations have not changed'. Preferred agents remain entecavir, TDF, or TAF. THE SIX 2026 RECOMMENDATIONS: (1) PMTCT, for pregnant persons with HBV DNA >200,000 IU/mL at any time point during pregnancy, regardless of HBeAg status, AASLD RECOMMENDS initiating TDF or TAF at gestational week 28 (STRONG recommendation, MODERATE certainty, the only strong recommendation in the guideline); TDF has a more extensive safety record in pregnancy than TAF. Implementation qualifiers: initiate immediately if care is first sought after week 28; initiate at week 16 if infant HBIG will be unavailable (with subsequent infant vaccination); consider earlier initiation when amniocentesis is anticipated (transmission risk is increased with HBV DNA >2,000,000 IU/mL) or when preterm labor risk is high; continue TDF/TAF if already on it, switch entecavir or other agents to TDF/TAF; if treatment was solely for perinatal prophylaxis it may be discontinued at delivery, with HBV DNA and ALT monitored every 1-3 months for up to 6 months for withdrawal flare and treatment reinitiated if ALT >=5x ULN; use TDF or TAF in breastfeeding persons requiring treatment. (2) HORIZONTAL TRANSMISSION, for HBsAg-positive viremic persons not meeting disease-specific treatment indications who are in high-risk scenarios for transmission to others, AASLD SUGGESTS a shared decision-making approach regarding antiviral treatment (CONDITIONAL, VERY LOW certainty). Qualifiers the guideline stresses: the decision weighs exposure risk and the vaccine/immunity status of contacts, favoring treatment if contacts are unvaccinated, vaccine-nonresponsive, immunocompromised, or of unknown vaccine status; persons requesting treatment for prevention may be prescribed it since risks may not be disclosed; explicitly, people with CHB must NOT be restricted in daily activities, contact sports, school, or professional training and must NOT be required to take antivirals because of transmission risk in those settings; routine contact, shared meals, and hugging are not transmission routes (avoid sharing toothbrushes/razors); most healthcare workers with CHB are NOT high-risk, but those performing SHEA Category III exposure-prone procedures may require antivirals (SHEA target HBV DNA <1000 IU/mL); neither CDC nor SHEA requires disclosure to patients or staff; anti-stigma framing is part of the recommendation. (3) IMMUNE-TOLERANT PHASE, defined as HBeAg-positive, HBV DNA >10^7 IU/mL, and normal ALT; AASLD SUGGESTS antiviral therapy for those over age 40 years, OR with significant liver inflammation (grade >=2) or fibrosis (>=F2) on biopsy or noninvasive tests (CONDITIONAL, VERY LOW certainty). For persons under age 40 who are interested in starting treatment earlier, AASLD suggests shared decision-making weighing risk factors and the benefits and risks of treatment. Accurate phase identification requires persistently normal ALT on >=2 measurements >=6 months apart, using ULN 35 U/L (males) and 25 U/L (females). (4) INDETERMINATE ('grey zone') PHASE, the HBeAg-negative indeterminate phase is defined as HBsAg-positive, HBeAg-negative persons whose ALT and/or HBV DNA fall outside the thresholds for HBeAg-negative immune-active CHB (ALT >2x ULN and HBV DNA >2,000 IU/mL) and outside those for inactive CHB (HBV DNA <2,000 IU/mL with normal ALT), comprising predominantly two subgroups, (I) normal (<ULN) or mildly elevated (<2x ULN) ALT with HBV DNA >=2,000 IU/mL, or (II) elevated ALT (>ULN) with HBV DNA <2,000 IU/mL, with ALT interpreted against ULN 35 U/L (males) and 25 U/L (females) and phase assigned on >=2 ALT and HBV DNA measurements over a 6-12 month period; in adults who are HBsAg-positive, HBeAg-negative, without cirrhosis and in the indeterminate phase so defined, AASLD SUGGESTS antiviral therapy using a shared decision-making approach assessing risks and benefits, and re-evaluating that decision at each follow-up visit if treatment has not been initiated (CONDITIONAL, VERY LOW certainty). Decision-relevant factors include fibrosis stage, age, and sex, e.g. age >40, male sex, and low-normal platelets (<180 k/mm3) favor treatment. (5) DISCONTINUATION, in adults with CHB who are HBeAg-negative, without cirrhosis, with sustained undetectable HBV DNA on nucleos(t)ide analogue therapy, AASLD SUGGESTS NOT withdrawing NA therapy until HBsAg loss (CONDITIONAL, VERY LOW certainty). If a patient nonetheless has a strong desire to stop, shared decision-making applies and ALL of the following must be met: no history of advanced fibrosis/cirrhosis, hepatic decompensation (variceal bleed, ascites, encephalopathy, hepatorenal syndrome), HCC, or extrahepatic HBV complications; if HBeAg-positive at treatment start, HBeAg seroconversion to anti-HBe-positive for >=1 year with undetectable HBV DNA >=2 years; if HBeAg-negative at start, undetectable HBV DNA >=2 years; no HIV or HDV coinfection; quantitative HBsAg <100 IU/mL; and willingness to adhere to frequent monitoring. After stopping, monitor ALT and HBV DNA every 1-3 months for 6 months, then every 3 months for 6-12 months, then every 3-6 months. Restart antivirals IMMEDIATELY if HBV DNA >=10,000 IU/mL (4 log IU/mL) at any time regardless of ALT, OR ALT >=5x ULN regardless of HBV DNA, OR total bilirubin >2.5 mg/dL. (6) HCC SURVEILLANCE (all CONDITIONAL, VERY LOW certainty; modality/interval per AASLD 2023 HCC Practice Guidance), Rec 6: after HBsAg loss, continue surveillance in those with cirrhosis, family history of HCC, men who lost HBsAg after age 40, and women who lost HBsAg after age 50. Rec 7: in HBV-HDV coinfection, surveil adults independent of cirrhosis status; in children, individualize because HCC risk in that population is unknown. Rec 8: in HBV-HIV coinfection, surveil men >=18 years and women >=40 years. Rec 9: in HBV-HCV coinfection, AASLD recommends treating HCV and suggests HCC surveillance per HBV mono-infection criteria. Where a person has more than one coinfection, the surveillance recommendation should follow the coinfection carrying the highest associated risk. The guideline notes that most of its recommendations rest on low or very low certainty evidence and that shared decision-making, not uniform policy, is the intended mode of application.

American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026 · reviewed 2026-07-23 ↗
Huang SC, Liu CJ · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
Hepatology prospective cohort · n=230 · Nov 11, 2026 · Clin Gastro Hep · IF 16.2

Sedating Medications and the Risk of Falls, Hospitalizations, and Hepatic Encephalopathy in Cirrhosis: A Prospective Cohort.

New evidencecirrhosishepatic encephalopathyepidemiology
Clinical takeawaySedating medication use (gabapentinoids, TCAs, benzodiazepines, anticholinergics, non-benzodiazepine hypnotics, antipsychotics, opioids) marks higher fall and hospitalization risk in cirrhosis, with ≥2 drugs associated with about twice the hazard; the authors call for trials of medication review and deprescribing.
What it foundIn 230 patients with cirrhosis, each additional sedating medication was associated with a 30-34% higher hazard of falls (sHR 1.30-1.34) and a 40-48% higher hazard of hospitalization (sHR 1.40-1.48).
ContextProspective multicentre cohort; overt HE reached significance in the MELD-Na and Child-Pugh adjusted model (sHR 1.93, 95% CI 1.03-3.63), and neither nonselective beta-blockers nor diuretics were associated with falls or hospitalization.
Measured against the standard of care· ACG 2026 (Bajaj JS, Jakab SS, Jesudian AB, et al. Am J Gastroenterol 2026;121(3):588-618) / EASL 2022

In adults with cirrhosis, hepatic encephalopathy (HE) is a clinical diagnosis. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

In adults with cirrhosis, hepatic encephalopathy (HE) is a clinical diagnosis. It is graded by West Haven (minimal plus grade 1 = covert; grades 2-4 = overt) and made only after other causes of altered mentation are excluded. Routine brain imaging is not needed in a patient with cirrhosis and confusion. Do not routinely check serum ammonia to guide HE treatment (conditional, very low certainty), and do not use ammonia alone to diagnose minimal or covert HE (conditional, very low). Ammonia should not be used to grade overt HE or to titrate therapy, though EASL 2022 notes that a normal level calls the diagnosis into question. For covert or minimal HE, use a single psychometric or neurophysiological test rather than two in combination (conditional, very low). Lactulose is suggested over no treatment for covert or minimal HE (conditional, low), but the evidence is insufficient to recommend routine treatment to prevent overt HE. In every episode of overt HE, search for and treat precipitants: infection, GI bleeding, dehydration or diuretic excess, electrolyte disturbance, constipation, sedatives. Reassess if the patient has not improved within 48-72 h. Lactulose is first-line for overt HE (strong, moderate), titrated to 2-3 soft bowel movements a day, given orally or by enema in grade 3-4. High-volume polyethylene glycol (about 4 L) is suggested as an alternative to lactulose (conditional, low). In acute inpatient overt HE, adding rifaximin to lactulose is suggested over lactulose alone (conditional, low). After a first episode of overt HE, give lactulose as secondary prophylaxis titrated to 2-3 BM/day. Outpatient rifaximin is suggested to prevent recurrence (conditional, low). Adding rifaximin 550 mg twice daily to lactulose is strongly recommended for recurrence while on lactulose (strong, high). If symptoms persist on lactulose plus rifaximin, zinc may be added when blood zinc is low (conditional, very low). Do not restrict protein (conditional, very low). Target protein 1.2-1.5 g/kg/day (strong, moderate) and give a late-evening snack (conditional, very low). Use BCAA supplementation when food alone cannot meet protein needs (strong, moderate). Before elective TIPS in decompensated cirrhosis, start rifaximin 14 days ahead and continue it for at least 6 months, with or without prior overt HE (strong, moderate). Extrahepatic collaterals may be embolized at the time of TIPS to reduce post-TIPS HE (conditional, low). For HE refractory to optimized medical therapy, embolization of a spontaneous portosystemic shunt is suggested in patients with adequate hepatic function and no contraindications (conditional, very low). Post-TIPS refractory HE may warrant TIPS reduction. Refer for transplant evaluation in patients with recurrent or persistent HE. In patients with multiple HE episodes and MELD <15, evaluate candidacy for living-donor liver transplant (conditional, low). Give oral and written advice against driving.

ACG 2026 (Bajaj JS, Jakab SS, Jesudian AB, et al. Am J Gastroenterol 2026;121(3):588-618) / EASL 2022 · reviewed 2026-10-11 ↗
Tapper EB … Serper M · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatology rct · n=300 · Nov 11, 2026 · Lancet GH · IF 39.1

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.

New therapyMASLDbiomarker
Clinical takeawayAwait phase 3 trial results and regulatory approval before considering pemvidutide for MASH patients with F2-F3 fibrosis.
What it foundPemvidutide 1.8 mg reduced liver fat content by 54.7% vs placebo's 8.2% at 48 weeks in MASH patients with F2-F3 fibrosis.
ContextThis extends prior 24-week findings, confirming pemvidutide's efficacy in reducing liver fat in MASH, a condition with limited treatment options. Liver biopsies were not collected at 48 weeks, limiting conclusions on fibrosis.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)

Decision at stakethe choice of pharmacotherapy for adults with non-cirrhotic MASH and F2-F3 fibrosis

… Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.

EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798) · reviewed 2026-10-11 ↗
Noureddin M … Harris MS · Lancet Gastroenterology & Hepatology · IF 39.1 · PubMed ↗Permalink
Hepatology retrospective · n=147 · Nov 11, 2026 · Clin Gastro Hep · IF 16.2

TIPS for refractory hepatic hydrothorax in patients with cirrhosis: impact of clinical response on survival.

New evidencecirrhosisportal hypertensionhepatic encephalopathyascites
Clinical takeawayIn patients selected for TIPS for refractory hydrothorax, expect complete response in about 60%; complete response was independently associated with lower mortality (HR 0.30, 95% CI 0.14-0.64), but the 147-patient series had no comparison group without TIPS.
What it foundTIPS achieved complete response (disappearance of symptoms and no further thoracenteses) in 60% of patients with refractory hepatic hydrothorax, with mortality rates of 1.54, 5.34, and 11.4 deaths per 100 patient-months in complete, partial, and no response groups, respectively.
ContextThis study provides evidence supporting TIPS as a potential option for refractory hepatic hydrothorax, though further research is needed to confirm its role in improving survival outcomes.
Emergingsuggested applicable standard· AASLD, 'Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis', Hepatology 2024 (PMID 37870298) - current AASLD guidance for the portal-hypertension context in which TIPS is indicated. Procedure-specific: AASLD 'The Role of TIPS in the Management of Portal Hypertension' (Boyer & Haskal), Hepatology 2010, doi 10.1002/hep.23383.

TIPS is a percutaneous interventional-radiology procedure that creates a covered (PTFE-preferred) shunt between portal and hepatic veins to decompress portal hypertension, indicated for refractory ascites (Child-Pugh A/B, MELD <18), refractory variceal hemorrhage, EARLY/pre-emptive placement within 72 h for Child-Pugh C ≤13 (or Child-Pugh B with active bleeding) at index EGD, Budd-Chiari syndrome, and select other decompensation states. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

TIPS is a percutaneous interventional-radiology procedure that creates a covered (PTFE-preferred) shunt between portal and hepatic veins to decompress portal hypertension, indicated for refractory ascites (Child-Pugh A/B, MELD <18), refractory variceal hemorrhage, EARLY/pre-emptive placement within 72 h for Child-Pugh C ≤13 (or Child-Pugh B with active bleeding) at index EGD, Budd-Chiari syndrome, and select other decompensation states. HVPG is measured pre/post with a target reduction ≥20% or HVPG ≤12 mmHg. All patients require pre-procedure cardiac/pulmonary/renal/LT evaluation. Post-procedure encephalopathy prophylaxis (e.g., lactulose and/or rifaximin) should be individualized based on risk factors such as prior HE, age >65, or severe liver dysfunction, with Doppler surveillance for stent dysfunction.

AASLD, 'Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis', Hepatology 2024 (PMID 37870298) - current AASLD guidance for the portal-hypertension context in which TIPS is indicated. Procedure-specific: AASLD 'The Role of TIPS in the Management of Portal Hypertension' (Boyer & Haskal), Hepatology 2010, doi 10.1002/hep.23383. · reviewed 2026-07-21 ↗
Tizzani M … “TIPS for refractory hydrothorax in cirrhosis” study investigators team · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink

Pancreas/Biliary· 2

Pancreas/Biliary prospective cohort · n=641,915 · Nov 9, 2026 · J Hepatobil Pancreat Sci · IF 3.8

Nationwide Trends in Perioperative Transfusion and Mortality by Hospital Surgical Volume in Biliary Tract Surgery.

New evidenceepidemiologyhealth servicesbiliary stricture
Clinical takeawayHospital volume and transfusion were associated with 30-day mortality in administrative data, and the excess with transfusion may partly reflect operative complexity and severity; the authors call for further evaluation of selective centralization.
What it found30-day mortality declined from 0.5% to 0.3% over 8 years; highest-volume hospitals had lower mortality among transfused patients (3.3% vs. 4.4% in lowest-volume hospitals), despite higher transfusion rates (4.8% vs. 3.9%). Mortality increased across transfusion-volume categories (p-trend < 0.0001).
ContextNationwide Korean insurance cohort, 2012 to 2020; volume-mortality patterns among transfused patients were more prominent in tertiary referral hospitals.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Yoon J … Park B · Journal of Hepato-Biliary-Pancreatic Sciences · IF 3.8 · PubMed ↗Permalink
Pancreas/Biliary prospective cohort · n=387 · Nov 14, 2026 · J Gastroenterology · IF 5.7

Clinicopathological and prognostic features of pancreatic acinar cell carcinoma: a nationwide multicenter study in Japan.

New evidencepancreatic cancerepidemiology
Clinical takeawayIn this retrospective registry, resection and, for non-resectable disease, chemotherapy including FOLFIRINOX were associated with longer survival; treatments were not compared prospectively.
What it foundFive-year survival was 55.3% after resection vs 4.5% without (p < 0.001). In non-resected patients, absence of chemotherapy was associated with worse prognosis and FOLFIRINOX with longer survival; AFP-positive immunostaining and Ki-67 ≥30% were independent adverse factors.
ContextNationwide study of a rare malignancy (387 patients, 85 centres); older age, non-resection and advanced stage were independently associated with shorter survival, and total pancreatectomy and recurrence with lower survival after resection.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Kanno A … Japan Pancreas Society Clinical Research Promotion Committee Group (Corporate Authorship) · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink

Endoscopy· 2

Endoscopy prospective cohort · n=134 · Nov 12, 2026 · Am J Gastro · IF 9.8

A Prospective Tandem Colonoscopy Study to Determine Proximal Colon Polyp Miss Rate Among Gastroenterology Trainees.

New evidencecolonoscopypolypectomyendoscopy qualityadenoma
Clinical takeawayConsider tandem colonoscopy assessments during training to objectively measure trainee polyp miss rates, particularly for sessile serrated polyps in the proximal colon.
What it foundTrainees missed 42.6% of proximal colon neoplastic polyps, including 38.1% of tubular adenomas and 58.9% of sessile serrated polyps.
ContextChallenges the reliance on adenoma detection rate (ADR) alone as a metric for trainee competence, highlighting the need for more objective measures of colonoscopy quality.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Siegel A … Keswani RN · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Endoscopy retrospective · n=1,217 · Nov 12, 2026 · J Clin Gastro · IF 2.9

Natural History and Predictors of Progression in Gastric Intestinal Metaplasia: An Australian Longitudinal Cohort Study.

New evidenceepidemiologybiomarker
Clinical takeawayContinue to follow the standard of care for surveillance in patients with extensive GIM or family history of gastric cancer
What it foundGIM patients had a 7.2% progression rate to dysplasia or cancer vs. 0.5% in non-GIM patients, with family history of GC (HR=4.9) and extensive GIM (HR=8.0) as independent predictors.
ContextThis literature reports that gastric intestinal metaplasia (GIM) is a premalignant lesion with a low progression rate to dysplasia or gastric cancer, highlighting its potential role in endoscopic surveillance.
Reinforcessuggested applicable standard· European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP), "Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Guideline update 2025", Endoscopy, 2025 (Recommendations 31 and 34)

Decision at stakefollow up patients with extensive endoscopic changes or advanced histological stage

… Follow up patients with extensive endoscopic changes (Kimura C3+ or EGGIM 5+) OR an advanced histological stage that reaches OLGA/OLGIM III/IV, severe atrophy or intestinal metaplasia and/or significant changes in both antrum and corpus rising to stage III/IV, not any intestinal metaplasia or any antrum-plus-corpus involvement on its own, with high quality endoscopy every 3 years, irrespective of country of origin (strong recommendation, moderate quality). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perform individual gastric risk assessment and staging of precancerous conditions at first-time gastroscopy, irrespective of the patient's country of origin. Use high quality endoscopy with virtual chromoendoscopy (VCE), after proper training, for screening, diagnosis and staging of atrophy and intestinal metaplasia and after endoscopic therapy; VCE guides the biopsy site, with random biopsies taken only when there are no endoscopically suspected changes. Take biopsies from at least two topographic sites, 2 from the antrum/incisura and 2 from the corpus, VCE-guided, in two separate, clearly labeled vials; an additional incisura biopsy is optional, not required. Stage with validated endoscopic classifications of atrophy (e.g. Kimura-Takemoto) or intestinal metaplasia (e.g. EGGIM) to stratify gastric cancer risk (suggestion, weaker than the biopsy recommendation). Follow up patients with extensive endoscopic changes (Kimura C3+ or EGGIM 5+) OR an advanced histological stage that reaches OLGA/OLGIM III/IV, severe atrophy or intestinal metaplasia and/or significant changes in both antrum and corpus rising to stage III/IV, not any intestinal metaplasia or any antrum-plus-corpus involvement on its own, with high quality endoscopy every 3 years, irrespective of country of origin (strong recommendation, moderate quality). Propose NO surveillance for patients with mild to moderate atrophy or intestinal metaplasia restricted to the antrum, in the absence of endoscopic signs of extensive lesions or other risk factors (family history of gastric cancer, incomplete intestinal metaplasia, persistent H. pylori infection), the guideline states this group constitutes most individuals found in clinical practice. Eradicate H. pylori in all patients with precancerous conditions and after endoscopic or surgical therapy. Discontinue or do not start gastric cancer screening or surveillance in asymptomatic individuals over 80, and weigh comorbidities when planning treatment of superficial lesions. Advise smoking cessation; low-dose daily aspirin may be considered for gastric cancer prevention only in selected individuals already at high cardiovascular risk. For visible neoplasia, use ESD for differentiated lesions clinically staged as dysplastic (low or high grade) or intramucosal carcinoma (any size if not ulcerated, or ≤30 mm if ulcerated), with EMR an alternative for Paris 0-IIa lesions ≤10 mm with low likelihood of malignancy. At the population level, endoscopic screening is suggested every 2-3 years in high-risk regions (age-standardized rate >20 per 100,000 person-years), every 5 years in intermediate-risk regions (ASR 10-20) only if cost-effectiveness has been proven, and not at all in low-risk regions (ASR <10).

European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP), "Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Guideline update 2025", Endoscopy, 2025 (Recommendations 31 and 34) · reviewed 2026-07-23 ↗
Tjandra D … Boussioutas A · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink

Colorectal· 1

Colorectal review · Nov 12, 2026 · Lancet · IF 98.4

Lynch syndrome.

Guideline / reviewLynch syndromebasic sciencetranslationalguideline
Clinical takeawayColonoscopic surveillance, aspirin chemoprevention and risk-reducing surgery are effective but need gene-specific, individualised application; carriers are found through universal tumour MMR testing followed by germline testing and cascade screening of relatives.
What it foundLynch syndrome affects approximately one in 350-450 individuals, and most carriers are undiagnosed. Universal tumour testing for MMR deficiency has transformed case identification and enabled targeted germline testing and cascade screening of relatives, but implementation is inconsistent, with attrition across diagnostic pathways and inequities in access.
ContextA review spanning biology, diagnosis, prevention and treatment, including substantial checkpoint-inhibitor benefit in MMR-deficient tumours and emerging vaccine strategies; it stresses equitable, effective health-system delivery.
Measured against the standard of care· ACG 2026 (adenomatous polyposis: Mankaney et al., Am J Gastroenterol 2026;121:2086-2120) / ACG 2015 (Lynch, SPS: Syngal et al.)

… Asymptomatic APC carriers, biallelic MUTYH carriers, and untested people at risk for AFAP or MAP should have a baseline colonoscopy by age 18-20. … Lynch syndrome and serrated polyposis syndrome are outside the 2026 document, so the Lynch and SPS parts of the standard on file were not re-verified here: Lynch colonoscopy every 1-2 years from age 20-25, gyn and upper-GI surveillance, and SPS colonoscopy every 1-3 years with removal of polyps over 5 mm.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Polyposis syndromes are now governed by ACG 2026 (Mankaney G, Idos GE, Stoffel EM, Weiss JM, Shah S, Qayed E, Harnegie MP, Burke CA; Am J Gastroenterol 2026;121(9):2086-2120, GRADE). For polyposis, it replaces the 2015 ACG hereditary GI cancer guideline (Syngal et al.), Recommendations 10-11. Germline multigene panel testing is recommended for anyone with 20 or more cumulative lifetime colorectal adenomas (strong recommendation) and suggested for 10-19 adenomas (conditional, because the yield is lower). The 2015 polyposis testing trigger was more than 10 adenomas. Asymptomatic APC carriers, biallelic MUTYH carriers, and untested people at risk for AFAP or MAP should have a baseline colonoscopy by age 18-20. Colonoscopy then repeats every 1-3 years depending on the histology, size and number of polyps. It moves to every 3-6 months when there are many or large polyps, or high-grade dysplasia. This replaces the 2015 schedules of annual sigmoidoscopy/colonoscopy from puberty for classic FAP, colonoscopy every 1-2 years from the late teens for AFAP, and from age 25-30 for MAP. Whether at-risk children in classic-FAP families still start younger is not stated in the excerpt available at review; confirm against the full text. For FAP, AFAP and MAP, upper endoscopic surveillance that includes viewing the duodenal papilla is suggested over no surveillance (Recommendation 8, conditional). Duodenal management is still staged by Spigelman, which has acknowledged limits in sensitivity for duodenal and papillary cancer. The 2026 starting age and intervals for upper endoscopy are not stated in the excerpt available at review. The choice of operation (total colectomy with IRA, IPAA, or end ileostomy) is individualized by genotype, polyp distribution, cancer status, comorbidity and preference, with early referral to an experienced colorectal surgeon. IRA is generally favored with up to about 20 rectal adenomas and IPAA above that, though this is not a fixed cutoff. The rectum or pouch should be checked endoscopically every year after IRA or IPAA. Chemoprevention is recommended against as a substitute for colectomy when surgery is indicated. Whether 2026 keeps annual thyroid ultrasound is not stated in the excerpt available at review. Lynch syndrome and serrated polyposis syndrome are outside the 2026 document, so the Lynch and SPS parts of the standard on file were not re-verified here: Lynch colonoscopy every 1-2 years from age 20-25, gyn and upper-GI surveillance, and SPS colonoscopy every 1-3 years with removal of polyps over 5 mm.

ACG 2026 (adenomatous polyposis: Mankaney et al., Am J Gastroenterol 2026;121:2086-2120) / ACG 2015 (Lynch, SPS: Syngal et al.) · reviewed 2026-10-11 ↗
Ryan NAJ … Smith T · The Lancet · IF 98.4 · PubMed ↗Permalink

Nutrition· 1

Nutrition prospective cohort · n=242,464 · Nov 13, 2026 · JPEN · IF 3.2

Development and validation of severe muscle mass reduction cutoffs for GLIM Criteria in Japanese adults: A two-phase study.

New evidencemalnutritionbiomarkerepidemiology
Clinical takeawayConsider using these cutoffs in older Japanese outpatients and hospitalized adults to assess severe muscle mass reduction and stratify mortality risk, particularly in those undergoing dual-energy X-ray absorptiometry or bioelectrical impedance analysis. Further validation in other populations is needed.
What it foundSevere muscle mass reduction cutoffs for appendicular skeletal muscle mass index were <6.4 kg/m2 in men and <5.0 kg/m2 in women, and for fat-free mass index were <16.0 kg/m2 in men and <13.4 kg/m2 in women, associated with 2.04-fold higher mortality (95% CI: 1.97-2.12).
ContextThis study establishes specific cutoffs for severe muscle mass reduction in older Japanese adults, refining the Global Leadership Initiative on Malnutrition criteria and providing prognostic risk stratification. The cutoffs were validated in a nationwide cohort of hospitalized adults, showing a 2.04-fold higher mortality risk (95% CI: 1.97-2.12).
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Takagi S … Arai H · JPEN. Journal of Parenteral and Enteral Nutrition · IF 3.2 · PubMed ↗Permalink
Everything else this week36 that cleared the bar

Ranked below the cards above, not excluded: these met the bar and were read and scored the same way. One line each, grouped by subspecialty, highest signal first; click through for the paper.

IBD· 11

Also screened this week64 papers read, not selected

These cleared the journal filter and were read, but were not selected this week. A score means the paper was weighed: below 35 it fell short of the bar; at 35 or above, a check after scoring set it aside. A blank means it was set aside before scoring. Listed for anyone going deeper; no takeaway attached, because none was written. How we choose →

Hepatology· 18

Endoscopy· 25

How we choose

the same pipeline every week
01

Scan

Every new paper across 48 vetted GI, hepatology, and general-medicine journals.

02

Screen

Drop what is not a study: letters, editorials, corrections, case reports. Classify the rest.

03

Anchor

Compare each paper to the guideline standard it touches, and record how far it moves it.

04

Verify

An adversarial second pass checks every claim against its cited source.

05

Vet

Each issue is reviewed by a physician editor before it publishes.